STOCKHOLM, Nov. 12, 2020
STOCKHOLM, Nov. 12, 2020 /PRNewswire/ -- Cantargia AB's ("Cantargia") interim report for the period January until September 2020 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.
Significant events in the third quarter
Significant events after the end of the period
January - September 2020
Third quarter 2020
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on November 12, 2020.
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied clinically as combination therapy with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy show a higher response rate than would be expected from chemotherapy alone. Cantargia's second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Interim report Q3 2020 (English version) 2020-11-12
Interim report Q3 PR Eng 201112 Final